tebentafusp-tebn – Uses, Dosage, Side Effects, Interaction

Last updated: February 8, 2026Reviewed date: February 8, 2026Reading time: 14 min read
Patient Tools

Read, save, and share this guide

Use these quick tools to make this medical article easier to read, print, save, or share with a family member.

tebentafusp-tebn - Uses, Dosage, Side Effects, Interaction
Patient Mode

Understand this article easily

Switch between simple English and easy Bangla patient notes. This is for education and does not replace a doctor consultation.

Tebentafusp is a bispecific gp100 peptide-HLA-directed CD3 T cell engager used to treat unresectable or metastatic uveal melanoma. Tebentafusp is a gp100 peptide-HLA-directed CD3 T cell engager. It is a bispecific, fusion protein and first-in-class drug of immune-mobilizing monoclonal T cell receptors against cancer (ImmTACs),...

For severe symptoms, danger signs, pregnancy, child illness, or sudden worsening, seek urgent medical care.

বাংলা রোগী নোট এখনো যোগ করা হয়নি। পোস্ট এডিটরে “RX Bangla Patient Mode” বক্স থেকে সহজ বাংলা সারাংশ যোগ করুন।

এই তথ্য শিক্ষা ও সচেতনতার জন্য। এটি ডাক্তারি পরীক্ষা, রোগ নির্ণয় বা প্রেসক্রিপশনের বিকল্প নয়।

Article Summary

Tebentafusp is a bispecific gp100 peptide-HLA-directed CD3 T cell engager used to treat unresectable or metastatic uveal melanoma. Tebentafusp is a gp100 peptide-HLA-directed CD3 T cell engager. It is a bispecific, fusion protein and first-in-class drug of immune-mobilizing monoclonal T cell receptors against cancer (ImmTACs), a recently developed cancer immunotherapy with a novel mechanism of action. ImmTACs bind to target cancer cells that express a...

Key Takeaways

  • This article explains Mechanism of action in simple medical language.
  • This article explains Indications in simple medical language.
  • This article explains Contraindications in simple medical language.
  • This article explains Dosage in simple medical language.
Educational health guideWritten for patient understanding and clinical awareness.
Reviewed content workflowUse writer and reviewer profiles for stronger trust.
Emergency safety firstUrgent warning signs are highlighted below.
Choose your reading view

Patient View highlights a simple learning journey. Clinical View reveals structure, evidence, and editorial completeness.

Seek urgent medical care if you notice

These warning signs are general safety guidance. Local emergency numbers and clinical judgment should always come first.

  • Severe symptoms, breathing difficulty, fainting, confusion, or rapidly worsening illness.
  • New weakness, severe pain, high fever, or symptoms after a serious injury.
  • Any symptom that feels urgent, unusual, or unsafe for the patient.
1

Emergency now

Use emergency care for severe, sudden, rapidly worsening, or life-threatening symptoms.

2

See a doctor

Book a professional medical evaluation if symptoms persist, worsen, recur often, affect daily activities, or occur in a high-risk patient.

3

Learn safely

Use this article to understand possible causes, tests, treatment options, prevention, and questions to ask your clinician.

Before reading

RX Patient Tools

Use these quick guides before reading the article, or return to them when you need help preparing questions for a doctor.

Start here Choose the right pathway for symptoms, reports, medicines, or urgent warning signs. Disease article roadmap Read this topic step by step: meaning, symptoms, warning signs, diagnosis, treatment, prevention, and follow-up. Treatment planner Prepare questions about treatment choices, benefits, risks, side effects, and follow-up. Family & caregiver guide Organize symptoms, reports, medicines, questions, and follow-up safely. Nutrition & diet guide Prepare food, hydration, supplement, and medicine-timing questions safely. Prevention guide Organize risk factors, protective habits, screening, and warning signs. Recovery guide Prepare a safe plan for activity, rehabilitation, warning signs, and follow-up.
Definition

Tebentafusp is a bispecific gp100 peptide-HLA-directed CD3 T cell engager used to treat unresectable or metastatic uveal melanoma. Tebentafusp is a gp100 peptide-HLA-directed CD3 T cell engager. It is a bispecific, fusion protein and first-in-class drug of immune-mobilizing monoclonal T cell receptors against cancer (ImmTACs), a recently developed cancer immunotherapy with a novel mechanism of action. ImmTACs bind to target cancer cells that express a specific antigen of interest and recruit cytotoxic T cells to lyse the cells, such as melanocytes.[rx,rx]

Uveal melanoma is a rare ocular tumour with often poor prognosis and limited treatment options. Even after surgical ablation or removal of the ocular tumour, almost 50% of patients with uveal melanoma develop metastatic disease.[rx] On January 26, 2022, tebentafusp was first approved by the FDA for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma. This approval marks the first bispecific T cell engager to be approved by the FDA to treat a solid tumour and being the first and only therapy for the treatment of unresectable or metastatic uveal melanoma to be approved by the FDA.[rx] Tebentafusp was subsequently approved for the same indication in the EU in April 2022.[rx]

Mechanism of action

Glycoprotein 100 (gp100) is a transmembrane glycoprotein highly expressed in melanoma cells and weakly expressed by normal melanocytes or other tissues. Gp100 is presented as a human infection. সহজ বাংলা: শ্বেত রক্তকণিকা।" data-rx-term="leukocyte" data-rx-definition="Leukocyte means white blood cell, which helps fight infection. সহজ বাংলা: শ্বেত রক্তকণিকা।">leukocyte antigen (HLA)-peptide complex on the cell surface. Gp100 has a particularly high affinity for the HLA-A subtype HLA-A*02:01.[rx,rx] HLAs are part of a protein complex that normally regulates immune function: natural T cell responses are initiated by the interaction between the T-cell receptor (TCR) and its peptide antigen, such as gp100, presented by HLA on the surface of a target cell.[rx]

Tebentafusp is a bispecific gp100 peptide-HLA-A*02:01 directed T cell receptor CD3 T cell engager. It consists of a TCR targeting domain – or a TCR arm – fused to a single-chain variable fragment (scFv) anti-CD3 effector domain.[rx] The TCR arm binds to a gp100 peptide bound to HLA-A on the uveal melanoma tumour cell surface. The anti-CD3 effector domain of tebentafusp engages and activates CD3+ T cells to inflammatory cytokines and cytolytic proteins, which results in direct lysis of uveal melanoma tumour cells.[rx] The anti-CD3 fragment of the drug has a lower affinity, so the T cells are not stimulated unless tebentafusp has detected gp100.[rx]

Tebentafusp is only effective in HLA-A*02:01-positive patients.[rx,rx]

Tebentafusp is novel immunotherapy that causes cytotoxicity of cancer cells. Tebentafusp increased the serum levels of cytokines (IFN-γ, TNFα, IL-2, IL-6, IL-10 and IL-1RA) and chemokines (CXCL9, CXCL10, CXCL11, hepatocyte growth factor, and monocyte chemoattractant protein-1) during the first three doses. The levels of cytokines and chemokines peaked between eight to 24 hours after treatment, and levels returned to baseline before subsequent doses. In subsequent treatment cycles, cytokine elevation occurred in fewer patients with lesser intensity than the first three doses. Tebentafusp also reduced lymphocyte counts after the first three doses, which returned to baseline before subsequent doses.[rx] In phase III clinical trials, patients treated with tebentafusp showed a better overall survival rate compared to pembrolizumab, ipilimumab, or dacarbazine.[rx]

Indications

  • Tebentafusp, sold under the brand name Kimmtrak, is an anti-cancer medication used to treat uveal melanoma (eye cancer). Tebentafusp is a bispecific gp100 peptide-HLA-directed CD3 T cell engager.[rx][rx]
  • Tebentafusp is indicated for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.
  • Metastatic Uveal Melanoma (UM)
  • Unresectable Uveal Melanoma

Use in Cancer

Tebentafusp-tebn is approved to treat:

Tebentafusp-tebn is also being studied in the treatment of other types of cancer.

Contraindications

  • abnormal liver function tests
  • pregnancy
  • a patient who is producing milk and breastfeeding

Dosage

Strengths: tebn 100 mcg/0.5 mL

Malignant Melanoma

  • 20 mcg IV on Day 1, 30 mcg IV on Day 8, 68 mcg IV on Day 15, and then 68 mcg IV once a week thereafter
  • Duration of therapy: Until unacceptable toxicity or disease progression occurs
  • Patient selection should be based on a positive human infection. সহজ বাংলা: শ্বেত রক্তকণিকা।" data-rx-term="leukocyte" data-rx-definition="Leukocyte means white blood cell, which helps fight infection. সহজ বাংলা: শ্বেত রক্তকণিকা।">leukocyte antigen-A*02:01 (HLA-A*02:01) genotyping test.
  • A US FDA-approved test for the detection of HLA-A*02:01 genotyping is not currently available.
  • For the treatment of HLA-A*02:01-positive patients with unresectable or metastatic uveal melanoma

Dose Adjustments

No dosage reduction is recommended for this drug; the following dosage modifications are recommended for adverse reactions.

CYTOKINE RELEASE SYNDROME (CRS):

  • MODERATE defined as temperature at least 38C (100.4F) with hypotension that responds to fluids (does not require vasopressors) OR hypoxia requiring low flow nasal canula (up to 6 L/min) or blow-by oxygen:
  • If hypotension and hypoxia do not improve within 3 hours or CRS worsens, care should be escalated and signs/symptoms should be managed according to next higher level of severity.
  • For moderate CRS that is persistent (lasting 2 to 3 hours) or recurrent, corticosteroid premedication (e.g., dexamethasone 4 mg or equivalent) should be administered at least 30 minutes before the next dose.
  • SEVERE defined as temperature at least 38C with hemodynamic instability requiring a vasopressor (with or without vasopressin) OR worsening hypoxia or respiratory distress requiring high flow nasal canula (greater than 6 L/min oxygen) or face mask:
  • This drug should be withheld until CRS and sequelae have resolved.
  • IV corticosteroid (e.g., 2 mg/kg/day methylprednisolone or equivalent) should be administered.
  • This drug should resume at the same dose level (i.e., should not escalate if severe CRS occurred during initial dose escalation; escalation should resume once dosage is tolerated).
  • For severe CRS, corticosteroid premedication (e.g., dexamethasone 4 mg or equivalent) should be administered at least 30 minutes before the next dose.
  • LIFE-THREATENING is defined as a temperature at least 38C with hemodynamic instability requiring multiple vasopressors (excluding vasopressin) OR worsening hypoxia or respiratory distress despite oxygen administration requiring positive pressure:
  • This drug should be permanently discontinued.
  • IV corticosteroids (e.g., 2 mg/kg/day methylprednisolone or equivalent) should be administered.

SKIN REACTIONS:

  • Grade 2 or 3:
  • This drug should be withheld until grade 1 or lower or baseline.
  • This drug should resume at the same dose level (i.e., should not escalate if grade 3 skin reactions occurred during initial dose escalation; escalation should resume once the dosage is tolerated).
  • For persistent reactions not responding to oral steroids, IV corticosteroids (e.g., 2 mg/kg/day methylprednisolone or equivalent) should be considered.
  • Grade 4:
  • This drug should be permanently discontinued.
  • IV corticosteroids (e.g., 2 mg/kg/day methylprednisolone or equivalent) should be administered.

ELEVATED LIVER ENZYMES:

  • Grade 3 or 4:
  • This drug should be withheld until grade 1 or lower or baseline.
  • This drug should resume at the same dose level if the elevated liver enzymes occur in the setting of grade 3 CRS; escalation should resume if next administration is tolerated.
  • If the elevated liver enzymes occur outside the setting of grade 3 CRS, escalation should resume if the current dose is less than 68 mcg, or this drug should resume at the same dose level if escalation has completed.
  • IV corticosteroids should be administered if no improvement within 24 hours.

OTHER ADVERSE REACTIONS:

  • Grade 3:
  • This drug should be withheld until grade 1 or lower or baseline.
  • This drug should resume at same dose level (i.e., should not escalate if other grade 3 adverse reactions occurred during initial dose escalation; escalation should resume once dosage is tolerated).
  • Grade 4:
  • This drug should be permanently discontinued.

Grade is based on National Cancer Institute Common Terminology Criteria for Adverse Events.

Administration advice:

  • Administer the first 3 infusions in an appropriate health care setting; monitor patients during the infusion and for at least 16 hours after the infusion is complete.
  • If the patient does not have grade 2 or worse hypotension (requiring medical intervention) during or after the third infusion, administer subsequent doses in an appropriate ambulatory care setting; monitor patients for at least 30 minutes after each of these infusions.
  • Administer the diluted solution immediately via IV infusion over 15 to 20 minutes through a dedicated IV line.
  • Use a sterile, nonpyrogenic, low protein binding 0.2-micron in-line filter infusion set.
  • Administer the entire contents of the infusion bag.
  • Do not mix this drug with other drugs or administer other drugs through the same IV line.
  • After the infusion is complete, flush the infusion line with an adequate volume of sterile 0.9% Sodium Chloride Injection, USP to ensure the entire contents of the infusion bag have been administered.

Reconstitution/preparation techniques:

  • A 2-step dilution process is required to prepare the final dose for infusion.
  • The manufacturer’s product information should be consulted.
  • Compatible: Albumin (Human); 0.9% Sodium Chloride Injection, USP
  • This drug should not be mixed with other drugs.

Monitoring:

  • Dermatologic: For skin reactions
  • Hepatic: ALT, AST, and total blood jaundice. সহজ বাংলা: জন্ডিসে বাড়তে পারে এমন হলুদ রঞ্জক।" data-rx-term="bilirubin" data-rx-definition="Bilirubin is a yellow pigment that can build up in jaundice. সহজ বাংলা: জন্ডিসে বাড়তে পারে এমন হলুদ রঞ্জক।">bilirubin (before starting and during therapy)
  • Immunologic: For signs/symptoms of CRS (after administration)
  • Investigations: Fluid status, vital signs, oxygenation level
  • Read the US FDA-approved patient labeling (Patient Information).
  • Immediately contact the health care provider if signs/symptoms associated with CRS (e.g., pyrexia, hypotension, hypoxia, chills, nausea, vomiting, fatigue, pain in the head or upper neck. সহজ বাংলা: মাথাব্যথা।" data-rx-term="headache" data-rx-definition="Headache means pain in the head or upper neck. সহজ বাংলা: মাথাব্যথা।">headache) occur.
  • Contact health care provider if signs/symptoms of progressive/intolerable skin reactions develop.
  • Contact health care provider if signs/symptoms of liver toxicity (e.g., right-sided abdominal pain, jaundice, scleral icterus) develop.
  • Patients of childbearing potential: Notify your health care provider if you are pregnant or become pregnant; use effective contraception while receiving this drug and for 1 week after the last dose.
  • Do not breastfeed during therapy and for 1 week after the last dose.

Side Effects

The Most Common

  • rash
  • skin redness, itching, or swelling
  • lightening or darkening of the skin
  • hair color changes or hair loss
  • constipation
  • swelling of the arms or legs
  • decreased appetite
  • pain in arms, legs, back, or joints
  • mouth or throat pain
  • pain or discomfort in right upper stomach area or yellowing of the skin or eyes
  • pain: Back pain means pain in the spine, muscles, discs, joints, or nerves of the back. সহজ বাংলা: পিঠ/কোমরের ব্যথা।" data-rx-term="back pain" data-rx-definition="Back pain means pain in the spine, muscles, discs, joints, or nerves of the back. সহজ বাংলা: পিঠ/কোমরের ব্যথা।">Back pain
  • burning, crawling, itching, numbness, prickling, “pins and needles”, or tingling feelings
  • constipation
  • difficulty in moving
  • dry skin
  • joint pain or swelling
  • lightening of the normal skin color
  • loss or thinning of the hair
  • muscle aches, cramps, pain, or stiffness
  • night sweats
  • pain in the arms or legs
  • runny nose
  • shivering
  • sore throat
  • trouble sleeping

More common

  • Blurred vision
  • chills
  • confusion
  • diarrhea
  • dizziness
  • dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
  • faintness
  • fast, pounding, or irregular heartbeat or pulse
  • feeling of warmth
  • fever
  • general feeling of discomfort or illness
  • headache
  • muscle or joint pain
  • nausea
  • nervousness
  • pounding in the ears
  • rash, itching, or skin swelling
  • redness of the face, neck, arms and occasionally, upper chest
  • redness of the skin
  • sweating
  • unusual tiredness or weakness
  • unusually warm skin
  • vomiting

Rare

  • Anxiety
  • chest pain
  • clay colored stools
  • cough
  • dark urine
  • loss of appetite
  • problems with movement, walking, or speech
  • seizures
  • stomach pain or tenderness
  • swelling of the feet or lower legs
  • trouble breathing
  • yellow eyes or skin

Drug Interaction

Pregnancy and Lactation

US FDA pregnancy category: Not assigned.

Pregnancy

Based on the mechanism of action, KIMMTRAK may cause fetal harm when administered to a pregnant woman. There are no available data with KIMMTRAK in pregnant women. No animal reproductive and developmental toxicity studies have been conducted with KIMMTRAK. Molecules of similar molecular weight can cross the placenta resulting in fetal exposure. Advise women of the potential risk to the fetus. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%-4% and 15%-20%, respectively.

Lactation

There are no data on the presence of tebentafusp-tebn in human milk, the effect on the breastfed child, or the effects on milk production. Because tebentafusp-tebn may be excreted in human milk and because of the potential for serious adverse reactions in a breastfed child, advise patients not to breastfeed during treatment with KIMMTRAK and for at least 1 week after the last dose.

Why is this medication prescribed?

Tebentafusp injection is used to treat certain types of uveal melanoma (cancer of the eye) that is unable to be surgically removed or has spread to other parts of the body. Tebentafusp is in a class of medications called CD3 T cell receptor engagers. It works by stimulating the immune system to kill cancer cells.

How should this medicine be used?

Tebentafusp injection comes as a liquid and is injected intravenously (into a vein) by a doctor or nurse in a healthcare setting. It is usually injected slowly over period of 15 to 20 minutes once a week. The length of your treatment depends on how well your body responds to the medication and the side effects that you experience. Ask your pharmacist or doctor for a copy of the manufacturer’s information for the patient. This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.

What special precautions should I follow?

Before receiving tebentafusp injection,

  • tell your doctor and pharmacist if you are allergic to tebentafusp, any other medications, or any of the ingredients in tebentafusp injection. Ask your pharmacist for a list of the ingredients.
  • tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, or nutritional supplements, you are taking or plan to take. Your doctor may need to change the doses of your medications or monitor you carefully for side effects.
  • tell your doctor if you have or have ever had liver disease.
  • tell your doctor if you are pregnant, or plan to become pregnant. You should not become pregnant while you are taking receiving tebentafusp injection. You will need to have a pregnancy test before you start your treatment with tebentafusp. You should use birth control to prevent pregnancy during your treatment with tebentafusp injection and for 1 week after the final dose. Talk to your doctor about birth control methods that you can use. Tebentafusp may harm your unborn baby. If you become pregnant while receiving tebentafusp injection, call your doctor.
  • tell your doctor if you are breastfeeding. You should not breastfeed while you are receiving tebentafusp injection and for at least 1 week after your final dose.

  1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761228s000lbl.pdf
  2. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tebentafusp-tebn-unresectable-or-metastatic-uveal-melanoma
  3. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/761228Orig1s000AdminCorres.pdf
  4. https://www.cancer.gov/about-cancer/treatment/drugs/tebentafusp-tebn
  5. https://pubchem.ncbi.nlm.nih.gov/substance/178103950
  6. https://go.drugbank.com/drugs/DB15283
  7. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9514125/
  8. https://www.drugs.com/mtm/tebentafusp.html
  9. https://medlineplus.gov/druginfo/meds/a622033.html
  10. https://www.webmd.com/drugs/2/drug-183440/tebentafusp-tebn-intravenous/details/list-contraindications
  11. https://www.mayoclinic.org/drugs-supplements/tebentafusp-tebn-intravenous-route/side-effects/drg-20529404

RX Clinical Pathway Engine

Continue through a complete learning pathway

Move from understanding the topic to symptoms, tests, treatment, medicines, monitoring, and prevention.

Search the complete library
  1. Understand the condition Begin with the essential facts and a clear explanation of the topic.
  2. Recognize symptoms Learn common symptoms, signs, and patterns of presentation.
  3. Know when to seek help Review urgent warning signs and when professional assessment may be needed.
  4. Understand causes and risks Explore causes, risk factors, mechanisms, and contributing conditions.
  5. Explore tests and diagnosis Learn how clinicians assess the condition and which investigations may be discussed.
  6. Learn treatment approaches Review general treatment categories and management principles.
  7. Understand medicines safely Continue to medicine education, uses, precautions, and monitoring.
  8. Plan monitoring and follow-up Understand monitoring, complications, rehabilitation, and follow-up learning.
  9. Review prevention and self-care Explore prevention, healthy routines, and questions to discuss with a clinician.

Conditions & Diseases

Background, symptoms, causes, diagnosis, and care.

Explore this library

Tests & Investigations

Laboratory, imaging, screening, and diagnostic education.

Explore this library

Medicines

Uses, safety, monitoring, and related medicine knowledge.

Explore this library

Cancer Knowledge

Cancer types, screening, oncology, and treatment education.

Explore this library
Doctor visit helper

Prepare before seeing a doctor

A simple rural-patient checklist to help you explain symptoms clearly, ask better questions, and avoid unsafe self-treatment.

Safety note: This is not a prescription or diagnosis. For severe symptoms, pregnancy danger signs, children with serious illness, chest pain, breathing difficulty, stroke-like weakness, or major injury, seek urgent care.

Which doctor may help?

Start with a registered doctor or the nearest qualified health center.

What to tell the doctor

  • Write when the problem started and how it changed.
  • Bring old prescriptions, investigation reports, and current medicines.
  • Write allergies, pregnancy status, diabetes, kidney/liver disease, and major past illnesses.
  • Bring one family member if the patient is weak, elderly, confused, or a child.

Questions to ask

  • What is the most likely cause of my symptoms?
  • Which danger signs mean I should go to hospital quickly?
  • Which tests are necessary now, and which can wait?
  • How should I take medicines safely and what side effects should I watch for?
  • When should I come for follow-up?

Tests to discuss

  • Vital signs: temperature, pulse, blood pressure, oxygen saturation
  • Basic physical examination by a clinician
  • CBC, urine test, blood sugar, or imaging only when clinically needed

Avoid these mistakes

  • Do not use antibiotics, steroid tablets/injections, or strong painkillers without proper medical advice.
  • Do not hide pregnancy, kidney disease, ulcer, allergy, or blood thinner use.
  • Do not delay emergency care when danger signs are present.

Medicine safety and first-aid guide

This section is for patient education only. It does not replace a doctor, pharmacist, or emergency care.

Safe first steps

  • Avoid heavy lifting, sudden bending, and prolonged bed rest.
  • Use comfortable posture and gentle movement as tolerated.
  • Discuss physiotherapy, X-ray, or MRI only when clinically needed.

OTC medicine safety

  • For mild back pain, pain-relief medicine may be discussed with a doctor or pharmacist.
  • Avoid repeated painkiller use if you have kidney disease, stomach ulcer, uncontrolled blood pressure, or are taking blood thinners.

Avoid these mistakes

  • Do not start antibiotics without a proper medical decision.
  • Do not use steroid tablets or injections casually for quick relief.
  • Do not delay emergency care because of home remedies.

Get urgent help if

  • Back pain with leg weakness, numbness around private area, loss of urine/stool control, fever, cancer history, or major injury needs urgent care.
Medicine names, dose, and timing must be decided by a qualified clinician or pharmacist after checking age, pregnancy, allergy, other diseases, and current medicines.

For rural patients and family caregivers

Patient health record and symptom diary

Write your symptoms, medicines already taken, test results, and questions before visiting a doctor. This note stays on your device unless you print or copy it.

Doctor to discuss: Orthopedic / spine specialist, physical medicine doctor, or qualified clinician
Tests to discuss with doctor
  • Neurological examination for leg power, sensation, reflexes, and straight leg raise
  • X-ray only if injury, deformity, long-lasting pain, or doctor suspects bone problem
  • MRI discussion if severe nerve symptoms, weakness, bladder/bowel problem, or persistent symptoms
Questions to ask
  • What is the most likely cause of my symptoms?
  • Which warning signs mean I should go to emergency care?
  • Which tests are really needed now?
  • Which medicines are safe for my age, pregnancy status, allergy, kidney/liver/stomach condition, and current medicines?
  • Is physiotherapy, posture correction, or activity modification needed?

Emergency warning signs such as chest pain, severe breathing difficulty, sudden weakness, confusion, severe dehydration, major injury, or loss of bladder/bowel control need urgent medical care. Do not wait for online information.

Safe pathway to proper treatment

Care roadmap for: tebentafusp-tebn – Uses, Dosage, Side Effects, Interaction

Use this simple roadmap to understand the next safe steps. It is educational and does not replace examination by a doctor.

Go to emergency care if you notice:
  • Severe or rapidly worsening symptoms
  • Breathing difficulty, chest pain, fainting, confusion, severe weakness, major injury, or severe dehydration
Doctor / service to discuss: Qualified healthcare provider; specialist depends on symptoms and examination.
  1. Step 1

    Check danger signs first

    If danger signs are present, seek emergency care and do not wait for online information.

  2. Step 2

    Record the symptom story

    Write when symptoms started, severity, medicines already taken, allergies, pregnancy status, and test results.

  3. Step 3

    Visit a qualified clinician

    A doctor, nurse, or qualified healthcare provider can examine you and decide which tests or treatment are needed.

  4. Step 4

    Do only useful tests

    Do tests after clinical assessment. Avoid unnecessary tests, random antibiotics, or repeated medicines without diagnosis.

  5. Step 5

    Follow up and return early if worse

    If symptoms worsen, new warning signs appear, or treatment is not helping, return for review quickly.

Rural patient practical tips
  • Take a written symptom diary and all previous prescriptions/test reports.
  • Do not hide medicines already taken, even herbal or over-the-counter medicines.
  • Ask which warning signs mean urgent referral to hospital.

This roadmap is for education. A real diagnosis and treatment plan requires history, examination, and clinical judgment.

RX Patient Help

Ask a health question safely

Write your symptom story. A health professional or site editor can review it before any answer is prepared. This box is not for emergency care.

Emergency first: Severe chest pain, breathing trouble, unconsciousness, stroke signs, severe injury, heavy bleeding, or rapidly worsening symptoms need urgent local medical care now.

Frequently Asked Questions

Mechanism of action Glycoprotein 100 (gp100) is a transmembrane glycoprotein highly expressed in melanoma cells and weakly expressed by normal melanocytes or other tissues. Gp100 is presented as a human leukocyte antigen (HLA)-peptide complex on the cell surface. Gp100 has a particularly high affinity for the HLA-A subtype HLA-A*02:01.[rx,rx] HLAs are part of a protein complex that normally regulates immune function: natural T cell responses are initiated by the interaction between the T-cell receptor (TCR) and its peptide antigen, such as gp100, presented by HLA on the surface of a target cell.[rx] Tebentafusp is a bispecific gp100 peptide-HLA-A*02:01 directed T cell receptor CD3 T cell engager. It consists of a TCR targeting domain - or a TCR arm - fused to a single-chain variable fragment (scFv) anti-CD3 effector domain.[rx] The TCR arm binds to a gp100 peptide bound to HLA-A on the uveal melanoma tumour cell surface. The anti-CD3 effector domain of tebentafusp engages and activates CD3+ T cells to inflammatory cytokines and cytolytic proteins, which results in direct lysis of uveal melanoma tumour cells.[rx] The anti-CD3 fragment of the drug has a lower affinity, so the T cells are not stimulated unless tebentafusp has detected gp100.[rx] Tebentafusp is only effective in HLA-A*02:01-positive patients.[rx,rx] Tebentafusp is novel immunotherapy that causes cytotoxicity of cancer cells. Tebentafusp increased the serum levels of cytokines (IFN-γ, TNFα, IL-2, IL-6, IL-10 and IL-1RA) and chemokines (CXCL9, CXCL10, CXCL11, hepatocyte growth factor, and monocyte chemoattractant protein-1) during the first three doses. The levels of cytokines and chemokines peaked between eight to 24 hours after treatment, and levels returned to baseline before subsequent doses. In subsequent treatment cycles, cytokine elevation occurred in fewer patients with lesser intensity than the first three doses. Tebentafusp also reduced lymphocyte counts after the first three doses, which returned to baseline before subsequent doses.[rx] In phase III clinical trials, patients treated with tebentafusp showed a better overall survival rate compared to pembrolizumab, ipilimumab, or dacarbazine.[rx] Indications Tebentafusp, sold under the brand name Kimmtrak, is an anti-cancer medication used to treat uveal melanoma (eye cancer). Tebentafusp is a bispecific gp100 peptide-HLA-directed CD3 T cell engager.[rx][rx] Tebentafusp is indicated for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma. Metastatic Uveal Melanoma (UM) Unresectable Uveal Melanoma Use in Cancer Tebentafusp-tebn is approved to treat: Uveal melanoma that cannot be removed by surgery or has spread to other parts of the body. It is used in adults who have the HLA-A*02:01 antigen. Tebentafusp-tebn is also being studied in the treatment of other types of cancer. Contraindications abnormal liver function tests pregnancy a patient who is producing milk and breastfeeding Dosage Strengths: tebn 100 mcg/0.5 mL Malignant Melanoma 20 mcg IV on Day 1, 30 mcg IV on Day 8, 68 mcg IV on Day 15, and then 68 mcg IV once a week thereafter Duration of therapy: Until unacceptable toxicity or disease progression occurs Patient selection should be based on a positive human leukocyte antigen-A*02:01 (HLA-A*02:01) genotyping test. A US FDA-approved test for the detection of HLA-A*02:01 genotyping is not currently available. For the treatment of HLA-A*02:01-positive patients with unresectable or metastatic uveal melanoma Dose Adjustments No dosage reduction is recommended for this drug; the following dosage modifications are recommended for adverse reactions. CYTOKINE RELEASE SYNDROME (CRS): MODERATE defined as temperature at least 38C (100.4F) with hypotension that responds to fluids (does not require vasopressors) OR hypoxia requiring low flow nasal canula (up to 6 L/min) or blow-by oxygen: If hypotension and hypoxia do not improve within 3 hours or CRS worsens, care should be escalated and signs/symptoms should be managed according to next higher level of severity. For moderate CRS that is persistent (lasting 2 to 3 hours) or recurrent, corticosteroid premedication (e.g., dexamethasone 4 mg or equivalent) should be administered at least 30 minutes before the next dose. SEVERE defined as temperature at least 38C with hemodynamic instability requiring a vasopressor (with or without vasopressin) OR worsening hypoxia or respiratory distress requiring high flow nasal canula (greater than 6 L/min oxygen) or face mask: This drug should be withheld until CRS and sequelae have resolved. IV corticosteroid (e.g., 2 mg/kg/day methylprednisolone or equivalent) should be administered. This drug should resume at the same dose level (i.e., should not escalate if severe CRS occurred during initial dose escalation; escalation should resume once dosage is tolerated). For severe CRS, corticosteroid premedication (e.g., dexamethasone 4 mg or equivalent) should be administered at least 30 minutes before the next dose. LIFE-THREATENING is defined as a temperature at least 38C with hemodynamic instability requiring multiple vasopressors (excluding vasopressin) OR worsening hypoxia or respiratory distress despite oxygen administration requiring positive pressure: This drug should be permanently discontinued. IV corticosteroids (e.g., 2 mg/kg/day methylprednisolone or equivalent) should be administered. SKIN REACTIONS: Grade 2 or 3: This drug should be withheld until grade 1 or lower or baseline. This drug should resume at the same dose level (i.e., should not escalate if grade 3 skin reactions occurred during initial dose escalation; escalation should resume once the dosage is tolerated). For persistent reactions not responding to oral steroids, IV corticosteroids (e.g., 2 mg/kg/day methylprednisolone or equivalent) should be considered. Grade 4: This drug should be permanently discontinued. IV corticosteroids (e.g., 2 mg/kg/day methylprednisolone or equivalent) should be administered. ELEVATED LIVER ENZYMES: Grade 3 or 4: This drug should be withheld until grade 1 or lower or baseline. This drug should resume at the same dose level if the elevated liver enzymes occur in the setting of grade 3 CRS; escalation should resume if next administration is tolerated. If the elevated liver enzymes occur outside the setting of grade 3 CRS, escalation should resume if the current dose is less than 68 mcg, or this drug should resume at the same dose level if escalation has completed. IV corticosteroids should be administered if no improvement within 24 hours. OTHER ADVERSE REACTIONS: Grade 3: This drug should be withheld until grade 1 or lower or baseline. This drug should resume at same dose level (i.e., should not escalate if other grade 3 adverse reactions occurred during initial dose escalation; escalation should resume once dosage is tolerated). Grade 4: This drug should be permanently discontinued. Grade is based on National Cancer Institute Common Terminology Criteria for Adverse Events. Administration advice: Administer the first 3 infusions in an appropriate health care setting; monitor patients during the infusion and for at least 16 hours after the infusion is complete. If the patient does not have grade 2 or worse hypotension (requiring medical intervention) during or after the third infusion, administer subsequent doses in an appropriate ambulatory care setting; monitor patients for at least 30 minutes after each of these infusions. Administer the diluted solution immediately via IV infusion over 15 to 20 minutes through a dedicated IV line. Use a sterile, nonpyrogenic, low protein binding 0.2-micron in-line filter infusion set. Administer the entire contents of the infusion bag. Do not mix this drug with other drugs or administer other drugs through the same IV line. After the infusion is complete, flush the infusion line with an adequate volume of sterile 0.9% Sodium Chloride Injection, USP to ensure the entire contents of the infusion bag have been administered. Reconstitution/preparation techniques: A 2-step dilution process is required to prepare the final dose for infusion. The manufacturer's product information should be consulted. Compatible: Albumin (Human); 0.9% Sodium Chloride Injection, USP This drug should not be mixed with other drugs. Monitoring: Dermatologic: For skin reactions Hepatic: ALT, AST, and total blood bilirubin (before starting and during therapy) Immunologic: For signs/symptoms of CRS (after administration) Investigations: Fluid status, vital signs, oxygenation level Read the US FDA-approved patient labeling (Patient Information). Immediately contact the health care provider if signs/symptoms associated with CRS (e.g., pyrexia, hypotension, hypoxia, chills, nausea, vomiting, fatigue, headache) occur. Contact health care provider if signs/symptoms of progressive/intolerable skin reactions develop. Contact health care provider if signs/symptoms of liver toxicity (e.g., right-sided abdominal pain, jaundice, scleral icterus) develop. Patients of childbearing potential: Notify your health care provider if you are pregnant or become pregnant; use effective contraception while receiving this drug and for 1 week after the last dose. Do not breastfeed during therapy and for 1 week after the last dose. Side Effects The Most Common rash skin redness, itching, or swelling lightening or darkening of the skin hair color changes or hair loss constipation swelling of the arms or legs decreased appetite pain in arms, legs, back, or joints mouth or throat pain pain or discomfort in right upper stomach area or yellowing of the skin or eyes Back pain burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings constipation difficulty in moving dry skin joint pain or swelling lightening of the normal skin color loss or thinning of the hair muscle aches, cramps, pain, or stiffness night sweats pain in the arms or legs runny nose shivering sore throat trouble sleeping More common Blurred vision chills confusion diarrhea dizziness dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position faintness fast, pounding, or irregular heartbeat or pulse feeling of warmth fever general feeling of discomfort or illness headache muscle or joint pain nausea nervousness pounding in the ears rash, itching, or skin swelling redness of the face, neck, arms and occasionally, upper chest redness of the skin sweating unusual tiredness or weakness unusually warm skin vomiting Rare Anxiety chest pain clay colored stools cough dark urine loss of appetite problems with movement, walking, or speech seizures stomach pain or tenderness swelling of the feet or lower legs trouble breathing yellow eyes or skin Drug Interaction DRUG INTERACTION Articaine The risk or severity of methemoglobinemia can be increased when Tebentafusp is combined with Articaine. Benzocaine The risk or severity of methemoglobinemia can be increased when Tebentafusp is combined with Benzocaine. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Tebentafusp is combined with Benzyl alcohol. Bupivacaine The risk or severity of methemoglobinemia can be increased when Tebentafusp is combined with Bupivacaine. Butacaine The risk or severity of methemoglobinemia can be increased when Tebentafusp is combined with Butacaine. Butamben The risk or severity of methemoglobinemia can be increased when Tebentafusp is combined with Butamben. Capsaicin The risk or severity of methemoglobinemia can be increased when Tebentafusp is combined with Capsaicin. Chloroprocaine The risk or severity of methemoglobinemia can be increased when Tebentafusp is combined with Chloroprocaine. Cinchocaine The risk or severity of methemoglobinemia can be increased when Tebentafusp is combined with Cinchocaine. Cocaine The risk or severity of methemoglobinemia can be increased when Tebentafusp is combined with Cocaine. Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Tebentafusp. Diphenhydramine The risk or severity of methemoglobinemia can be increased when Tebentafusp is combined with Diphenhydramine. Dyclonine The risk or severity of methemoglobinemia can be increased when Tebentafusp is combined with Dyclonine. Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Tebentafusp. Ethyl chloride The risk or severity of methemoglobinemia can be increased when Tebentafusp is combined with Ethyl chloride. Etidocaine The risk or severity of methemoglobinemia can be increased when Tebentafusp is combined with Etidocaine. Levobupivacaine The risk or severity of methemoglobinemia can be increased when Tebentafusp is combined with Levobupivacaine. Lidocaine The risk or severity of methemoglobinemia can be increased when Tebentafusp is combined with Lidocaine. Meloxicam The risk or severity of methemoglobinemia can be increased when Tebentafusp is combined with Meloxicam. Mepivacaine The risk or severity of methemoglobinemia can be increased when Tebentafusp is combined with Mepivacaine. Methoxy The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Tebentafusp. Oxetacaine The risk or severity of methemoglobinemia can be increased when Tebentafusp is combined with Oxetacaine. Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Tebentafusp is combined with Oxybuprocaine. Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Tebentafusp. Phenol The risk or severity of methemoglobinemia can be increased when Tebentafusp is combined with Phenol. Pramocaine The risk or severity of methemoglobinemia can be increased when Tebentafusp is combined with Pramocaine. Prilocaine The risk or severity of methemoglobinemia can be increased when Tebentafusp is combined with Prilocaine. Procaine The risk or severity of methemoglobinemia can be increased when Tebentafusp is combined with Procaine. Proparacaine The risk or severity of methemoglobinemia can be increased when Tebentafusp is combined with Proparacaine. Propoxycaine The risk or severity of methemoglobinemia can be increased when Tebentafusp is combined with Propoxycaine. Ropivacaine The risk or severity of methemoglobinemia can be increased when Tebentafusp is combined with Ropivacaine. Tetracaine The risk or severity of methemoglobinemia can be increased when Tebentafusp is combined with Tetracaine. Pregnancy and Lactation US FDA pregnancy category: Not assigned. Pregnancy Based on the mechanism of action, KIMMTRAK may cause fetal harm when administered to a pregnant woman. There are no available data with KIMMTRAK in pregnant women. No animal reproductive and developmental toxicity studies have been conducted with KIMMTRAK. Molecules of similar molecular weight can cross the placenta resulting in fetal exposure. Advise women of the potential risk to the fetus. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%-4% and 15%-20%, respectively. Lactation There are no data on the presence of tebentafusp-tebn in human milk, the effect on the breastfed child, or the effects on milk production. Because tebentafusp-tebn may be excreted in human milk and because of the potential for serious adverse reactions in a breastfed child, advise patients not to breastfeed during treatment with KIMMTRAK and for at least 1 week after the last dose. Why is this medication prescribed?

Tebentafusp injection is used to treat certain types of uveal melanoma (cancer of the eye) that is unable to be surgically removed or has spread to other parts of the body. Tebentafusp is in a class of medications called CD3 T cell receptor engagers. It works by stimulating the immune system to kill cancer cells.

How should this medicine be used?

Tebentafusp injection comes as a liquid and is injected intravenously (into a vein) by a doctor or nurse in a healthcare setting. It is usually injected slowly over period of 15 to 20 minutes once a week. The length of your treatment depends on how well your body responds to the medication and the side effects that you experience. Ask your pharmacist or doctor for a copy of the manufacturer's information for the patient. This medication may be prescribed for…

Continue exploring

Explore this topic across the RX Medical Library

Open a focused A–Z pathway or continue with closely related indexed articles. These links are educational and do not replace personal medical care.

Search this topic
Diseases A–Z Drugs A–Z Lab Tests A–Z Cancer A–Z
Diseases A–Z

Foodborne Illness (also foodborne disease and colloquially referred to as food poisoning)[rx] is any illness resulting from the spoilage of contaminated food, pathogenic bacteria, viruses, or parasites that…

More from this topic
  1. Vasodilator Drugs

    Vasodilator drugs relax and widen blood vessels, increasing blood flow. A few examples include ACE inhibitors, ARBs, calcium channel blockers, and nitrates.   DefinitionVasodilators are medicines that dilate...

    June 9, 2025 • Drugs (A - Z)
  2. Methamphetamine Hydrochloride – Uses, Dosage, Side Effects, Interaction

    Methamphetamine Hydrochloride is the hydrochloride salt form of methamphetamine, an amphetamine and sympathomimetic amine with CNS stimulating properties. Methamphetamine hydrochloride acts by facilitating the release of catecholamines, particularly noradrenaline and dopamine, from...

    June 5, 2025 • Drugs (A - Z)
  3. Methamphetamine – Uses, Dosage, Side Effects, Interactions

    Methamphetamine is a member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent. It has a role as a neurotoxin, a psychotropic drug,...

    June 5, 2025 • Drugs (A - Z)
  4. Vitamin D3 – Uses, Dosage, Side Effects, Interactions

    DefinitionCholecalciferol is a steroid? hormone produced in the skin when exposed to ultraviolet light or obtained from dietary sources. The active form of cholecalciferol, 1,25-dihydroxycholecalciferol (calcitriol) plays an important role...

    March 10, 2025 • Drugs (A - Z)
  5. Imidazole – Uses, Dosage, Side Effects, Interactions

    DefinitionImidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is...

    October 20, 2023 • Drugs (A - Z)
  6. Carbimazole

    Carbimazole is a member of the class of imidazoles that is methimazole in which the nitrogen-bearing hydrogen is converted into its methoxycarbonyl derivative. A prodrug for methimazole, carbimazole is...

    October 20, 2023 • Drugs (A - Z)
  7. Methylthiouracil – Uses, Dosage, Side Effects, Interactions

    DefinitionA thiourea antithyroid agent that inhibits the synthesis of thyroid? hormone. It is used in the treatment of hyperthyroidism?. Methylthiouracil is an organosulfur compound that is used in...

    October 20, 2023 • Drugs (A - Z)
  8. Propylthiouracil – Uses, Dosage, Side Effects, Interactions

    DefinitionPropylthiouracil is a Thyroid? Hormone Synthesis Inhibitor. The mechanism of action of propylthiouracil is as a Thyroid Hormone Synthesis Inhibitor. 6-propyl-2-thiouracil is a pyrimidine-thione consisting of uracil in which the...

    October 20, 2023 • Drugs (A - Z)
  9. Methimazole

    DefinitionMethimazole ( Metirox 5 and 10 mg) is a member of the class of imidazoles that it imidazole-2-thione in which a methyl group replaces the hydrogen that is attached to...

    October 20, 2023 • Drugs (A - Z)
  10. Mirogabalin – Uses, Dosage, Side Effects, Interactions

    DefinitionMirogabalin has been used in trials studying the treatment of Post-herpetic Neuralgia, Pain? Associated With Fibromyalgia, and Diabetic peripheral neuropathic pain. Mirogabalin is a medication designed...

    August 12, 2023 • Drugs (A - Z)